Pricing Log in Create free account
Saturday 17 October 2026 Export BOLT’s income statement to Excel — free account

Bolt Biotherapeutics, Inc.

BOLT Healthcare Biotechnology

In the quarter to June 2026, revenue fell 99.7%, EPS fell 2.47%, free cash flow grew 38.9% and total debt fell 14.3%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

4.06 0.18 −4.25%
Market cap
$8.2M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
4/9
Altman Z
−12.67
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.01
Total sells 0.13
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — 2 — — — — — 2 — — — —
Sell — — — — — — — — — — 3 —
Insider Ownership 3.02%

Capital & Financial Ratios $m

Market Cap 8.17
Revenue 4.70
Net Income (28.74)
Free Cash Flow (30.82)
Net Debt 0.74
Current Ratio 2.61 (at or above 1.5: strong)
Debt/Equity 1.47
P/E ratio 0.00
Fwd P/E (0.02) (negative: loss-making)
P/S ratio 1.46
P/B ratio 0.54
Past 5Y EPS Growth —
This Y EPS Growth (0.20%) (below 0%: weak)
Next Y EPS Growth (12.89%) (below 0%: weak)
Next Y revenue growth (100.00%) (below 0%: weak)
Next 5Y EPS Growth (19.99%) (below 0%: weak)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.6×, against a ten-year median of −2.7×; over the ten years it ranged from −52.2× in 2022 to 283× in 2021.
P/S against its own 10 years 14.13%
10-year low 10-year high
P/B against its own 10 years 85.22%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2019 Powerpack
2018 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 102 48 28 18
Receivables — — — —
Inventory — — — —
Other — — — —
106 51 30 21
2023 2024 2025 Q'26
Payables 3 2 1 1
ST’ Debt — — — —
Other — — — —
20 16 8 8

Compound Annual Growth %

10y 5y 3y
Sales — 101.61% 10.33%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 137.74% (46.34%)

Revenue $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 1 2 2 3 8
’24 5 1 1 0 8
’23 2 1 3 2 8
’22 1 1 2 1 6
’21 — — 1 1 1
’20 0 0 — — 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (8) (7) — — —
’25 (13) (10) (10) (7) (40)
’24 (17) (16) (14) (14) (61)
’23 (23) (15) (17) (14) (70)
’22 (24) (21) (13) (18) (77)
’21 (17) (4) (19) (18) (57)
’20 (10) (12) (13) (13) (47)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (8) (6) — — —
’25 (12) (10) (10) (7) (39)
’24 (17) (16) (14) (14) (61)
’23 (23) (15) (17) (14) (70)
’22 (25) (21) (14) (18) (78)
’21 (17) (5) (20) (18) (59)
’20 (10) (13) (14) (14) (51)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (4.31) (4.57) — — —
’25 (5.80) (4.46) (3.72) (3.84) (17.85)
’24 (5.60) (11.20) (8.00) (8.40) (33.00)
’23 (9.00) (9.60) (8.60) (9.40) (36.60)
’22 (12.80) (12.20) (11.60) (10.60) (47.20)
’21 (22.80) (12.80) (12.60) (14.60) (59.40)
’20 (83.13) (105.88) (94.71) (291.60) (577.80)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — 79.20 23.60 16.80 9.50 4.41

Analyst estimates 2026–2028

Powerpack
High — — — — — 861.40 99.80 40.60 31.20 12.60
People
People Employees — — — — 65 91 94 100 52 23
Revenue/emp, $m — — — 0.00 0.00 0.01 0.06 0.08 0.15 0.33
Income, $m
Income, $m Revenue — — — 0 0 1 6 8 8 8
Gross margin, % — — 0.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
EBT — — (12) (30) (61) (99) (88) (69) (63) (33)
EBT margin, % — — 0.00 (14,180.00) (26,289.18) (7,824.68) (1,537.76) (878.58) (820.78) (433.74)
Net income — 0 (12) (30) (61) (99) (88) (69) (63) (33)
Depreciation — — 0 0 1 4 2 (3) (1) 1
Per share, $
Per share, $ Revenue — — 0.00 2.16 2.20 0.76 3.07 4.17 4.03 4.12
Earnings — — (0.33) (305.94) (577.80) (59.40) (47.20) (36.60) (33.00) (17.85)
Cash flow — — (0.28) (264.22) (450.12) (34.38) (40.96) (36.77) (32.11) (21.31)
Capex — — 0.00 (5.10) (31.04) (1.41) (1.05) (0.11) 0.06 0.48
Free cash flow — — (0.28) (269.32) (481.16) (35.79) (42.00) (36.88) (32.05) (20.83)
Book value — — 0.35 317.54 3.32 150.68 91.82 59.63 29.96 14.17
Shares, m — — 35 0 0 2 2 2 2 2
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — — 0.00 0.00 109.10 8.93 5.57 2.66 1.33
P/B — — — 0.00 0.00 0.65 0.30 0.39 0.36 0.39
EV/Sales — — — 0.00 0.00 (1.14) (17.02) (5.19) (0.61) 0.35
EV/FCF — — — (1.09) (1.09) 0.03 1.24 0.59 0.08 (0.07)
Cash, $m
Cash, $m Operating cash flow — — (10) (26) (47) (57) (77) (70) (61) (40)
Capex — — 0 (1) (3) (2) (2) 0 0 1
Free cash flow — — (10) (27) (51) (59) (78) (70) (61) (39)
Balance, $m
Balance, $m Working capital — — 11 27 14 168 150 85 35 22
Total debt — — 0 7 9 22 20 17 23 20
Net debt — — (14) (28) (13) (164) (149) (85) (25) (8)
Shareholders’ equity — — 12 32 0 250 172 113 57 27
Returns, %
Returns, % ROA — — (145.09) (94.65) (127.86) (55.66) (32.90) (35.71) (48.66) (42.69)
ROIC — — 0.00 (493.51) 0.00 (67.63) (247.18) (170.15) (142.45) (119.22)
ROE — — 37.51 98.68 80.54 (135.83) (41.79) (48.69) (74.28) (79.75)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Bolt Biotherapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CSCIF COSCIENS Biopharma Inc. $8.6M 1.0× — +30.04% (above 0%: growing) n/m +113.30% (above 0%: growing) 55.27% 13.43% Compare
IMRN IMMURON $8.3M — (loss-making) — +757.00% (above 0%: growing) +12.00% (above 0%: growing) +42.55% (above 0%: growing) 72.16% 0.00% Compare
ADIL Adial Pharmaceuticals, Inc. $8.3M — (loss-making) — — n/m −263.66% (below 0%: shrinking) 0.00% 0.00% Compare
BOLT Bolt Biotherapeutics, Inc. $8.2M — (loss-making) — (loss-making) −99.72% (below 0%: shrinking) n/m +38.87% (above 0%: growing) 100.00% (167,480.00%)
SNTI Senti Biosciences, Inc. $8.1M — (loss-making) — (loss-making) −98.68% (below 0%: shrinking) n/m −7.48% (below 0%: shrinking) 100.00% (85,229.41%) Compare
QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR $8.1M — (loss-making) — — n/m −510.28% (below 0%: shrinking) 0.00% 0.00% Compare
XTLB XTL Biopharmaceuticals Ltd. $8.1M — (loss-making) — −39.32% (below 0%: shrinking) n/m +46.78% (above 0%: growing) 0.00% 0.00% Compare
KPTI Karyopharm Therapeutics Inc. $8.0M — (loss-making) — (loss-making) −11.86% (below 0%: shrinking) n/m −33.34% (below 0%: shrinking) 96.75% (67.38%) Compare
CNSP CNS Pharmaceuticals, Inc. $7.9M — (loss-making) — — n/m +33.70% (above 0%: growing) 0.00% 0.00% Compare
Median of peers $8.1M — — −11.86% — +13.11% 27.64% 0.00%

All 614 Biotechnology stocks →

Bolt Biotherapeutics, Inc. (BOLT) key facts

  • Concern: Bolt Biotherapeutics, Inc. reported a net loss of $33.4 million, or a loss of $17.85 per share, for fiscal 2025.
  • Bolt Biotherapeutics, Inc. (BOLT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, BOLT traded at $4.06, a market capitalization of $8.2 million.
  • Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 1.5× sales.
  • Return on equity was −79.8% and debt-to-equity 1.47.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −12.67 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Bolt Biotherapeutics, Inc. (BOLT) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/BOLT · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com